



Europass Curriculum Vitae

Personal information

Surname(s) / First name(s) **Morosi Carlo**

Address(es) Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy

Telephone(s) +39 02 2390 2366

Fax(es) +39 02 2390 2338

E-mail carlo.morosi@istitutotumori.mi.it

Nationality Italian

Date of birth 9 June 1962

Gender Male

Work experience

Dates From 2004 up today

Occupation or position held **Attending physician**

Main activities and responsibilities Chair radiologist for the Department of Pediatric Oncology and referent radiologist for the Department of soft tissue sarcomas in adults. Activity and interest mainly in clinical application of computerized tomography, angiography and ultrasound and a wide expertise in interventional radiology procedures. Since 2007 in charge of clinical trials in pediatric and adult soft tissue sarcomas.

Name and address of employer **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 Milano, Italy

Type of business or sector Department of Radiology

Dates From 1990 to 2004

Occupation or position held **Attending physician**

Main activities and responsibilities

Name and address of Employer **Ospedale Bassini**, Cinisello Balsamo, Milano, Italy

Type of business or sector Department of Radiology

Dates From 1986 to 1990

Occupation or position held **Resident and then fellow**

Main activities and responsibilities Research associate

Name and address of employer **Istituto Nazionale dei Tumori**, via G. Venezian 1, 20133 Milano, Italy

Type of business or sector Department of Radiology

Education and training

Dates From 1981 to 1987-88

Title of qualification awarded **Medical Degree (cum laude 11 march 1988)**

Principal subjects/occupational skills covered Medicine

Name and type of organisation providing education and training University of Milano, Italy

Dates From 1988 to 1992

Title of qualification awarded **Postgraduate School in Radiology (diploma cum laude 10 november 1992)**

Principal subjects/occupational skills covered Medicine

Name and type of organisation providing education and training University of Milano, Italy

Level in national or international classification

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s)

Self-assessment
European level ()*

English

| Understanding | | | | Speaking | | | | Writing | |
|---------------|--------------|---------|--------------|--------------------|--------------|-------------------|--------------|---------|--------------|
| Listening | | Reading | | Spoken interaction | | Spoken production | | | |
| B1 | Intermediate | B1 | Intermediate | B1 | Intermediate | B1 | Intermediate | B1 | Intermediate |

(*) *Common European Framework of Reference for Languages*

Clinical trials

- I involved in several clinical trials of Sarcoma and Pediatric UNIT. Phase II study on lapatinib in egfr/er2neu positive advanced chordoma
- Phase I/phase II study of cp-751,871 in patients with relapsed and/or refractory Ewing's sarcoma family of tumors - Protocol no. a4021020
- SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas.
- Randomized double blind phase III trial of Pazopanib versus Placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.
- Open label, multi-center, phase 2 study denosumab in subjects with giant cell tumor of bone.
- Open label multicentre randomized phase II study evaluating the addition of bevacizumab to chemotherapy in child and adolescent patients presenting with metastatic rhabdomyosarcoma and non- rhabdomyosarcoma soft tissue sarcoma (the Bernie study).
- Phase I/II study of cp-751, 871 in patients with relapsed and/or refractory Ewing's sarcoma family of tumors (Prot. No. a40221020).
- Phase II study aiming to evaluate the effectiveness and safety of everolimus associated with Imatinib as first line therapy in patients with gastrointestinal stromal tumor, characterized by mutation of the exon 18 of the gene PDGFRA (D842V).
- Phase II study of imatinib in combination with RAD001 (everolimus) in patients with advanced chordoma.
- Randomized phase III trial of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID

Publications

1. Indeterminate pulmonary nodules in non-rhabdomyosarcoma soft tissue sarcoma: A study of the European paediatric Soft Tissue Sarcoma Study Group.
Giraudo C, Schoot R, Cardoen L, Stramare R, Coppadoro B, Bisogno G, Bouhamama A, Brennan B, Brisse HJ, Orbach D, Coma A, Di Paolo PL, Fayard C, McDonald L, Moalla S, **Morosi C**, Pace E, Tang V, van Noesel MM, Ferrari A, van Rijn R. *Cancer*. 2023 Oct 17. doi: 10.1002/cncr.35061. Online ahead of print. PMID: 37846799
2. Corrigendum to "International Soft Tissue sarcoma Consortium (INSTRuCT) consensus statement: Imaging recommendations for the management of rhabdomyosarcoma" [*Eur. J. Radiol.* 166 (2023) 111012].
Schoot RA, van Ewijk R, von Witzleben AA, Kao SC, Hans Merks JHM, **Morosi C**, Pace E, Shulkin BL, Ferrari A, von Kalle T, van Rijn RR, Weiss AR, Sparber-Sauer M, Ter Horst SAJ, Beth McCarville M. *Eur J Radiol.* 2023 Sep 27;168:111108. doi: 10.1016/j.ejrad.2023.111108. Online ahead of print. PMID: 37774530
3. Quantitative diffusion-weighted MRI response assessment in rhabdomyosarcoma: an international retrospective study on behalf of the European paediatric Soft tissue sarcoma Study Group Imaging Committee.
van Ewijk R, Chatziantoniou C, Adams M, Bertolini P, Bisogno G, Bouhamama A, Caro-Dominguez P, Charon V, Coma A, Dandis R, Devalck C, De Donno G, Ferrari A, Fiocco M, Gallego S, Giraudo C, Glosli H, Ter Horst SAJ, Jenney M, Klein WM, Leemans A, Leseur J, Mandeville HC, McHugh K, Merks JHM, Minard-Colin V, Moalla S, **Morosi C**, Orbach D, Ording Muller LS, Pace E, Di Paolo PL, Perruccio K, Quaglietta L, Renard M, van Rijn RR, Ruggiero A, Sirvent SI, De Luca A, Schoot RA. *Pediatr Radiol.* 2023 Sep 8. doi: 10.1007/s00247-023-05745-z. Online ahead of print. PMID: 37682330
4. Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Secondino S, Pedrazzoli P, Basso S, Bossi P, Bianco A, Imarisio I, Pagani A, De Cicco M, Muscianisi S, Casanova M, **Morosi C**, Bergamini C, Benazzo M, Cossu Rocca M, Perotti C, Baldanti F, Zecca M, Licitra LF, Comoli P. *Front Immunol.* 2023 Jul 11;14:1208475. doi: 10.3389/fimmu.2023.1208475. eCollection 2023. PMID: 37497213
5. Six Surgical Stages in the Resection of Primary Right Retroperitoneal Liposarcoma: A Standardized Comprehensive Approach.
Radaelli S, Baia M, Drohan A, **Morosi C**, Sangalli C, Colombo C, Callegaro D, Fiore M, Gronchi A. *Ann Surg Oncol.* 2023 Oct;30(11):6896-6897. doi: 10.1245/s10434-023-13660-8. Epub 2023 Jun 10. PMID: 37301773
6. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R, Hindi N, Cruz Jurado J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón-Perez I, Sangalli C, Pérez Aguiar JL, Romero J, **Morosi C**, Sunyach MP, Fabbroni C, Romagosa C, Ranchere-Vince D, Dei Tos

7. Treating secondary malignant neoplasms: A burden of childhood cancer survivors.
Podda MG, Meazza C, Gattuso G, Sironi G, Nigro O, Bergamaschi L, Biassoni V, Casanova M, Chiaravalli S, Ferrari A, Luksch R, Puma N, Schiavello E, Spreafico F, Grampa P, Manoukian S, Vennarini S, Collini P, Daolio PA, Gennaro M, Guzzo M, **Morosi C**, Biasoni D, Massimino M, Terenziani M. Tumori. 2023 Oct;109(5):436-441. doi: 10.1177/03008916231160824. Epub 2023 Mar 24. PMID: 36964667 Free PMC article.
8. Long-term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single-institution case series analysis.
Giani C, Radaelli S, Miceli R, Gandola L, Sangalli C, Frezza AM, Provenzano S, Pasquali S, Bertulli R, Fiore M, Callegaro D, Casanova M, Chiaravalli S, Collini P, Dagrada GP, **Morosi C**, Zaffaroni N, Casali PG, Ferrari A, Gronchi A, Stacchiotti S. Cancer Med. 2023 May;12(9):10694-10703. doi: 10.1002/cam4.5829. Epub 2023 Mar 23. PMID: 36951537
9. Implications of an Underlying Beckwith-Wiedemann Syndrome for Wilms Tumor Treatment Strategies.
Quarello P, Carli D, Biasoni D, Gerocarni Nappo S, **Morosi C**, Cotti R, Garelli E, Zucchetti G, Spadea M, Tirtei E, Spreafico F, Fagioli F. Cancers (Basel). 2023 Feb 17;15(4):1292. doi: 10.3390/cancers15041292. PMID: 36831633 Free PMC article
10. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardses J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, **Morosi C**, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6. PMID: 36502615
11. Relapse after non-metastatic rhabdomyosarcoma: The impact of routine surveillance imaging on early detection and post-relapse survival.
Casanova M, Bergamaschi L, Chiaravalli S, **Morosi C**, Livellara V, Hovsepian S, Sironi G, Puma N, Nigro O, Gattuso G, Luksch R, Terenziani M, Spreafico F, Meazza C, Podda M, Biassoni V, Schiavello E, Gasparini P, Vennarini S, Massimino M, Ferrari A. Pediatr Blood Cancer. 2023 Feb;70(2):e30095. doi: 10.1002/pbc.30095. Epub 2022 Nov 21. PMID: 36411264
12. Gene expression-based dissection of inter-histotypes, intra-histotype and intra-tumor heterogeneity in pediatric tumors.
Ciceri S, Careno A, Iannó MF, Bertolotti A, **Morosi C**, Luksch R, Spreafico F, Collini P, Radice P, Massimino M, De Cecco L, Perotti D. Sci Rep. 2022 Oct 25;12(1):17837. doi: 10.1038/s41598-022-20536-6
13. Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables.
Bergamaschi L, Chiaravalli S, Livellara V, Sironi G, Puma N, Nigro O, Gattuso G, Luksch R, Terenziani M, Spreafico F, Meazza C, Podda M, Biassoni V, Schiavello E, Hovsepian S, **Morosi C**, Vennarini S, Massimino M, Casanova M, Ferrari A. Pediatr Blood Cancer. 2022 Oct 10:e30050. doi: 10.1002/pbc.30050. Online ahead of print. PMID: 36215173
14. Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival.
Morosi C, Bergamaschi L, Livellara V, Hassan V, Chiaravalli S, Calareso G, Luksch R, Terenziani M, Spreafico F, Meazza C, Podda M, Biassoni V, Schiavello E, Puma N, Gattuso G, Sironi G, Nigro O, Vennarini S, Massimino M, Casanova M, Ferrari A. Eur J Cancer. 2022 Nov;175:274-281. doi: 10.1016/j.ejca.2022.08.028. Epub 2022 Sep 26. PMID: 36174299
15. Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature.

- Nasca V, Frezza AM, **Morosi C**, Buonomenna C, Parafioriti A, Zappalà G, Bini F, Casali PG, Loppini M, Stacchiotti S. *Front Oncol*. 2022 Jul 19;12:953149. doi: 10.3389/fonc.2022.953149. eCollection 2022. PMID: 35928864 Free PMC article.
16. Renal tumor biopsy in patients with cT1b-T4-M0 disease susceptible to radical nephrectomy: analysis of safety, accuracy and clinical impact on definitive management.
Nazzani S, Zaborra C, Biondi D, Catanzaro M, Macchi A, Stagni S, Tesone A, Torelli T, Lanocita R, Cascella T, **Morosi C**, Spreafico C, Colecchia M, Marchianò A, Montanari E, Salvioni R, Nicolai N. *Scand J Urol*. 2022 Jun 29:1-6. doi: 10.1080/21681805.2022.2092549. Online ahead of print. PMID: 35766193
 17. Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single-center experience.
Ferrari A, Bergamaschi L, Chiaravalli S, Livellara V, Sironi G, Nigro O, Puma N, Gattuso G, **Morosi C**, Gasparini P, Caccavo R, Pecori E, Alessandro O, Vennarini S, Gandola L, Massimino M, Casanova M. *Pediatr Blood Cancer*. 2022 Jun 22:e29853. doi: 10.1002/pbc.29853. Online ahead of print. PMID: 35731852
 18. Risk of misclassification during diagnosis of malnutrition in retroperitoneal sarcoma patients.
Casirati A, Baia M, Vandoni G, Della Valle S, Greco G, **Morosi C**, Fiore M, Gronchi A, Gavazzi C. *Clin Nutr ESPEN*. 2022 Jun;49:459-465. doi: 10.1016/j.clnesp.2022.02.125. Epub 2022 Mar 4. PMID: 35623852
 19. How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group.
Jackson TJ, Brisse HJ, Pritchard-Jones K, Nakata K, **Morosi C**, Oue T, Irtan S, Vujanic G, van den Heuvel-Eibrink MM, Graf N, Chowdhury T; SIOP RTSG Biopsy Working Group. *Pediatr Blood Cancer*. 2022 Sep;69(9):e29702. doi: 10.1002/pbc.29702. Epub 2022 May 19. PMID: 35587187 Review.
 20. Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse.
Chiaravalli S, Bergamaschi L, Livellara V, Sironi G, Puma N, Nigro O, Gattuso G, Luksch R, Terenziani M, Spreafico F, Meazza C, Podda M, Biassoni V, Schiavello E, **Morosi C**, Massimino M, Casanova M, Ferrari A. *Eur J Cancer*. 2022 Jul;169:179-187. doi: 10.1016/j.ejca.2022.03.037. Epub 2022 May 14. PMID: 35576803
 21. Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases.
Ferrari A, Chiaravalli S, Bergamaschi L, Nigro O, Livellara V, Sironi G, Gasparini P, Pasquali S, Zaffaroni N, Stacchiotti S, **Morosi C**, Massimino M, Casanova M. *J Chemother*. 2022 Apr 26:1-5. doi: 10.1080/1120009X.2022.2067706. Online ahead of print. PMID: 35470779
 22. Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Dose-Response Analysis with Two Radiological Methods.
Romanò C, Mazzaglia S, Maccauro M, Spreafico C, Gabutti A, Maffi G, **Morosi C**, Cascella T, Mira M, De Nile MC, Aliberti G, Argiroffi G, Fuoco V, Bhoori S, Zanette C, Marchianò A, Seregini E, Mazzaferro V, Chiesa C. *Cancers (Basel)*. 2022 Feb 15;14(4):959. doi: 10.3390/cancers14040959. PMID: 35205712 Free PMC article.
 23. Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort.
Radaelli S, Pasquali S, Colombo C, Callegaro D, Sanfilippo R, Stacchiotti S, Provenzano S, Sangalli C, **Morosi C**, Barisella M, Miceli R, Fiore M, Gronchi A. *Eur J Surg Oncol*. 2022 Jan 21:S0748-7983(22)00004-X. doi: 10.1016/j.ejso.2022.01.003. Online ahead of print. PMID: 35153104
 24. Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
Groenendijk A, van Tinteren H, Jiang Y, de Krijger RR, Vujanic GM, Godzinski J, Rùbe C, Schenk JP, **Morosi C**, Pritchard-Jones K, Al-Saadi R, Vaidya SJ, Verschuur AC, Ramírez-Villar GL, Graf N, de Camargo B, Drost J, Perotti D, van den Heuvel-Eibrink MM, Brok J, Spreafico F, Mavinkurve-Groothuis AMC. *Eur J Cancer*. 2022 Mar;163:88-97. doi: 10.1016/j.ejca.2021.12.014. Epub 2022 Jan 15. PMID: 35042071 Free article.
 25. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network.
Baldi GG, Lo Vullo S, Grignani G, Vincenzi B, Badalamenti G, Mastore M, Buonomenna C, **Morosi C**, Barisella M,

Frezza AM, Provenzano S, Simeone N, Picozzi F, Mariani L, Casali PG, Stacchiotti S. *Cancer*. 2022 Apr 1;128(7):1439-1448. doi: 10.1002/cncr.34083. Epub 2022 Jan 13. PMID: 35026050

26. Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads.
Casella T, Garanzini EM, Lanocita R, **Morosi C**, Riva F, Greco G, Sposito C, Mazzaferro V, Marchianò A, Spreafico C. *Cardiovasc Intervent Radiol*. 2022 Jan;45(1):54-61. doi: 10.1007/s00270-021-02991-2. Epub 2021 Nov 24. PMID: 34820694
27. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz-Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, **Morosi C**, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Miceli R, Casali PG, Gronchi A. *Cancer*. 2022 Jan 1;128(1):85-93. doi: 10.1002/cncr.33895. Epub 2021 Oct 13. PMID: 34643947 *Clinical Trial*.
28. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, **Morosi C**, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. *Ann Oncol*. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21. PMID: 34560242 No abstract available.
29. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.
Strauss SJ, Frezza AM, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Tos APD, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Gronchi A, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Pousa AL, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, **Morosi C**, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Ladenstein R, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN, GENTURIS and ERNPaedCan. *Ann Oncol*. 2021 Sep 1:S0923-7534(21)04280-0. doi: 10.1016/j.annonc.2021.08.1995. Online ahead of print.
30. Diagnostic yield and accuracy of image-guided percutaneous core needle biopsy of paediatric solid tumours: An experience from Italy
Lisa Serati , *, **Carlo Morosi**, Francesco Barretta, Paola Collini, Giuseppina Calareso, Stefano Chiaravalli, Filippo Spreafico, Roberto Luksch, Andrea Ferrari, Maura Massimino, Alfonso Marchiano
Pediatric Hematology Oncology Journal 6 (2021)
31. MRI Characteristics of Pediatric Renal Tumors: A SIOP-RTSG Radiology Panel Delphi Study.
van der Beek JN, Watson TA, Nievelstein RAJ, Brisse HJ, **Morosi C**, Lederman HM, Coma A, Gavra MM, Vult von Steyern K, Lakatos K, Breyssem L, Varga E, Ducou Le Pointe H, Lequin MH, Schäfer JF, Mentzel HJ, Hötter AM, Calareso G, Swinson S, Kyncl M, Granata C, Aertsen M, Di Paolo PL, de Krijger RR, Graf N, Olsen ØE, Schenk JP, van den Heuvel-Eibrink MM, Littooi AS. *J Magn Reson Imaging*. 2021 Aug 6. doi: 10.1002/jmri.27878. Online ahead of print. PMID: 34363274
32. Nutritional management of chylous leakage following surgery for high-risk neuroblastoma in a toddler: a case report.

Casirati A, Mulazzani G, Luksch R, **Morosi C**, Biasoni D, Della Valle S. *Eur J Clin Nutr.* 2021 Aug 6. doi: 10.1038/s41430-021-00988-1. Online ahead of print. PMID: 34363053 No abstract available.

33. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, **Morosi C**, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. *Ann Oncol.* 2021 Jul 21:S0923-7534(21)02184-0. doi: 10.1016/j.annonc.2021.07.006. Online ahead of print. PMID: 34303806 No abstract available.
34. Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study.
Asaftei SD, Puma N, Paioli A, Petraz M, **Morosi C**, Podda M, Tamburini A, Palmerini E, Coccoli L, Grignani G, Manzitti C, Bertulli R, De Leonardis F, Rabusin M, Campello A, Tirtei E, Picci P, Prete A, Longhi A, Fagioli F, Luksch R. *Cancers (Basel).* 2021 Jun 18;13(12):3046. doi: 10.3390/cancers13123046. PMID: 34207428 Free PMC article.
35. Management of serious complications in intra-abdominal desmoid-type fibromatosis.
Bini F, Fiore M, Provenzano S, Bertulli R, Ottini A, Colombo C, Vitellaro M, Greco G, **Morosi C**, Gronchi A, Casali PG, Palassini E. *Cancer Rep (Hoboken).* 2021 Jun 24:e1411. doi: 10.1002/cnr2.1411. Online ahead of print. PMID: 34165246 Free article.
36. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma - joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology.
van Ewijk R, Schoot RA, Sparber-Sauer M, Ter Horst SAJ, Jehanno N, Borgwardt L, de Keizer B, Merks JHM, de Luca A, McHugh K, von Kalle T, Schäfer JF, van Rijn RR; Cooperative Weichteilsarkom Studiengruppe Imaging Group, the European Society of Paediatric Radiology Oncology Task Force and the European Paediatric Soft Tissue Sarcoma Study Group Imaging Committee. *Pediatr Radiol.* 2021 Jun 17. doi: 10.1007/s00247-021-05081-0. Online ahead of print. PMID: 34137936
37. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Zanchetta E, Ciniselli CM, Bardelli A, Colombo C, Stacchiotti S, Baldi GG, Provenzano S, Bertulli R, Bini F, Casale A, Greco FG, Ferrari A, Verderio P, Fiore M, Gronchi A, Casali PG, **Morosi C**, Palassini E. *Cancer Med.* 2021 Jul;10(13):4356-4365. doi: 10.1002/cam4.3973. Epub 2021 Jun 8. PMID: 34102009 Free PMC article.
38. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.
Stacchiotti S, Miah AB, Frezza AM, Messiou C, **Morosi C**, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladly RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A. *ESMO Open.* 2021 Jun;6(3):100170. doi: 10.1016/j.esmoop.2021.100170. Epub 2021 Jun 2. PMID: 34090171 Free PMC article. Review.
39. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin.
Fabbroni C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, **Morosi C**, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R. *Cancers (Basel).* 2021 Mar 22;13(6):1453. doi: 10.3390/cancers13061453. PMID: 33810165 Free PMC

article.

40. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network.
Frezza AM, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, Casali PG, Caraceni A, Grignani G, Gronchi A, Infante G, **Morosi C**, Saita L, Simeone N, Zaffaroni N, Vincenzi B, Stacchiotti S. *ESMO Open*. 2021 Apr;6(2):100083. doi: 10.1016/j.esmoop.2021.100083. Epub 2021 Mar 10. PMID: 33714008 Free PMC article.
41. Pediatric Rhabdomyosarcomas: Three-Dimensional Radiological Assessments after Induction Chemotherapy Predict Survival Better than One-Dimensional and Two-Dimensional Measurements.
Orsatti G, **Morosi C**, Giraudo C, Varotto A, Crimi F, Bonzini M, Minotti M, Frigo AC, Zanetti I, Chiaravalli S, Casanova M, Ferrari A, Bisogno G, Stramare R. *Cancers (Basel)*. 2020 Dec 17;12(12):3808. doi: 10.3390/cancers12123808. PMID: 33348683 Free PMC article.
42. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network.
Stacchiotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, Palassini E, Dagrada G, Collini P, **Morosi C**, Greco FG, Sbaraglia M, Dei Tos AP, Mariani L, Frezza AM, Casali PG. *Cancer*. 2021 Feb 15;127(4):569-576. doi: 10.1002/cncr.33247. Epub 2020 Oct 27. PMID: 33107985
43. Extraskelatal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management.
Stacchiotti S, Baldi GG, **Morosi C**, Gronchi A, Maestro R. *Cancers (Basel)*. 2020 Sep 21;12(9):E2703. doi: 10.3390/cancers12092703. PMID: 32967265 Review.
44. Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers.
Fucà G, Fabbroni C, Mancari R, Manglaviti S, Bogani G, Fumagalli E, Bertulli R, **Morosi C**, Collini P, Raspagliesi F, Colombo N, Casali PG, Sanfilippo R. *Clin Sarcoma Res*. 2020 Aug 28;10:17. doi: 10.1186/s13569-020-00139-3. eCollection 2020. PMID: 32874547 Free PMC article.
45. Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma: a prospective cohort study.
Massimino M, Podda M, Gandola L, Pignoli E, Seregni E, **Morosi C**, Spreafico F, Ferrari A, Pecori E, Terenziani M. *Front Med*. 2020 Aug 13. doi: 10.1007/s11684-020-0752-2. Online ahead of print. PMID: 32794013
46. Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution.
Perhavec A, Provenzano S, Baia M, Sangalli C, **Morosi C**, Barisella M, Colombo C, Radaelli S, Pasquali S, Callegaro D, Gronchi A, Fiore M. *Ann Surg Oncol*. 2020 Jul 6. doi: 10.1245/s10434-020-08789-9. Online ahead of print. PMID: 32632883
47. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, **Morosi C**, Greco FG, Frezza AM, Casali PG, Stacchiotti S. *ESMO Open*. 2020 Jul;5(4):e000663. doi: 10.1136/esmoopen-2019-000663. PMID: 32661185 Free PMC article.
48. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R, Fabbroni C, Fucà G, Fumagalli E, **Morosi C**, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG. *Clin Cancer Res*. 2020 Jun 30. doi: 10.1158/1078-0432.CCR-20-1191. Online ahead of print. PMID: 32605908
49. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Baldi GG, Brahmi M, Lo Vullo S, Cojocar E, Mir O, Casanova M, Vincenzi B, De Pas TM, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, Gronchi A, Collini P, Dei Tos AP, **Morosi C**, Mariani L, Casali PG, Stacchiotti S. *Oncologist*. 2020 Jun 25. doi: 10.1634/theoncologist.2020-0352. Online ahead of print. PMID: 32584482 Free article.
50. Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients.

- Massimino M, Sunyach MP, Barretta F, Gandola L, Garegnani A, Pecori E, Spreafico F, Bonneville-Levard A, Meyronet D, Mottolese C, Boschetti L, Biassoni V, Schiavello E, Giussani C, Carrabba G, Diletto B, Pallotti F, Stefani R, Ferrari A, Terenziani M, Casanova M, Luksch R, Meazza C, Podda M, Chiaravalli S, Puma N, Bergamaschi L, **Morosi C**, Calareso G, Giangaspero F, Antonelli M, Buttarelli FR, Frappaz D.J *Neurooncol.* 2020 Jul;148(3):619-628. doi: 10.1007/s11060-020-03564-y. Epub 2020 Jun 21.PMID: 32567042
51. Precocious pseudopuberty, a paraneoplastic manifestation: a report of 2 cases.
Gattuso G, Casanova M, Biassoni V, Terenziani M, Schiavello E, Sironi G, Collini P, Pallotti F, **Morosi C**, Massimino M.*Tumori.* 2020 May 28:300891620925532. doi: 10.1177/0300891620925532. Online ahead of print.PMID: 32462993
 52. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, **Morosi C**, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG.*J Clin Oncol.* 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18.PMID: 32421444
 53. Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma.
Tirotta F, **Morosi C**, Hodson J, Desai A, Barisella M, Ford SJ, Gronchi A, Almond LM, Fiore M.*Ann Surg Oncol.* 2020 Oct;27(11):4574-4581. doi: 10.1245/s10434-020-08519-1. Epub 2020 May 4.PMID: 32367501
 54. Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, Italiano A, Sargos P, Cruz-Jurado J, Isern-Verdum J, Dolado MC, Rincon-Pérez I, Sanchez-Bustos P, Gutierrez A, Romagosa C, **Morosi C**, Grignani G, Gatti M, Luna P, Alastuey I, Redondo A, Belinchon B, Martinez-Serra J, Sunyach MP, Coindre JM, Dei Tos AP, Romero J, Gronchi A, Blay JY, Moura DS. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.*JAMA Oncol.* 2020 Feb 20.
 55. Panarisi NAR, Cascella T, **Morosi C**, Greco FG, Marchianò A, Lanocita R. Contrast-Enhanced Ultrasound-Guided Percutaneous Biopsy of the Peritoneum: A Series of 3 Cases. *J Ultrasound Med.* 2020 Jan 27.
 56. Spreafico F, Ferrari A, Mascarin M, Collini P, Morosi C, Biasoni D, Biassoni V, Schiavello E, Gandola L, Gattuso G, Chiaravalli S, Massimino M. Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience.*Cancer Metastasis Rev.* 2019 Dec;38(4):683-694.
 57. Vaarwerk B, Mallebranche C, Affinita MC, van der Lee JH, Ferrari A, Chisholm JC, Defachelles AS, De Salvo GL, Corradini N, Minard-Colin V, **Morosi C**, Brisse HJ, McHugh K, Bisogno G, van Rijn RR, Orbach D, Merks JHM. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience.*Cancer.* 2020 Feb 15;126(4):823-831.
 58. Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, **Morosi C**, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2019 Sep;20(9):1252-1262.
 59. Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, **Morosi C**, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups *J.EClinicalMedicine.* 2019 Mar 11;9:35-43. doi: 10.1016/j.eclinm.2019.03.007. eCollection 2019 Mar.
 60. Bergamaschi L, Bertulli R, Casanova M, Provenzano S, Chiaravalli S, Gasparini P, Collini P, Sangalli C, Gandola L, Diletto B, **Morosi C**, Fiore M, Massimino M, Ferrari A. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series *Med Oncol.* 2019 May 18;36(7):59.
 61. Tirotta F, Fumagalli E, Colombo C, **Morosi C**, Barisella M, Radaelli S, Frezza AM, Casali PG, Gronchi A, Fiore M. JManagement of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors. *Surg Oncol.* 2019 May 7.

62. Vaarwerk B, Bisogno G, McHugh K, Brisse HJ, **Morosi C**, Corradini N, Jenney M, Orbach D, Chisholm JC, Ferrari A, Zanetti I, De Salvo GL, van Rijn RR, Merks JHM; E pSSG Radiology Group. Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group *J Clin Oncol*. 2019 Mar 20;37(9):723-730. doi: 10.1200/JCO.18.01535. Epub 2019 Jan 31.
63. Almond LM, Tirota F, Tattersall H, Hodson J, Cascella T, Barisella M, Marchianò A, Greco G, Desai A, Ford SJ, Gronchi A, Fiore M, **Morosi C**. Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma *Br J Surg*. 2019 Mar;106(4):395-403. doi: 10.1002/bjs.11064. Epub 2019 Jan 24.
64. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, **Morosi C**, Stacchiotti S, Casali PG, Gronchi A. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patients-A propensity score analysis. *J Surg Oncol*. 2019 Mar;119(3):318-323.
65. Stacchiotti S, Simeone N, Lo Vullo S, **Morosi C**, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. *Eur J Cancer*. 2019 Jan;106:225-233. doi: 10.1016/j.ejca.2018.10.024. Epub 2018 Dec 5.
66. Stacchiotti S, **Morosi C**, Lo Vullo S, Casale A, Palassini E, Frezza AM, Dinoi G, Messina A, Gronchi A, Cavalleri A, Venturelli E, Morelli D, Pilotti S, Collini P, Brici S, Tamborini E, Mariani L, Casali PG
Imatinib and Everolimus in patients with progressive advanced chordoma: a phase 2 clinical study
Cancer 2018 Sep 14
67. Raimondi A, Colombo F, Pintarelli G, **Morosi C**, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, Stacchiotti S
Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor
A case report and literature review
Anticancer Drugs. 2018 Jul;29(6):589-595
68. Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, **Morosi C**, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V.
Development of a prognostic score to predict response to Yttrium -90 radioembolization for hepatocellular carcinoma with portal vein invasion
J Hepatol. 2018 Jan 10.
69. Messiou C, **Morosi C**
Imaging in retroperitoneal soft tissue sarcoma
J Surg Oncol. 2018 Jan; 117(1): 25-32.
70. Meazza C, Cefalo G, Massimino M, Daolio P, Pastorino U, Scanagatta P, **Morosi C**, Podda M, Ferrari A, Terenziani M, Spreafico F, Casanova M, Parafioriti A, Collini P, Gandola L, Bastoni S, Biassoni V, Schiavello E, Chiaravalli S, Puma N, Bergamaschi L, Luksch R.
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
Med Oncol. 2017 Nov 1;34(12):191.
71. Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, **Morosi C**, Collini P, Gronchi A, Casali PG, Sanfilippo R.
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.
Sarcoma. 2017;2017:3739159. :
72. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, **Morosi C**, Tos APD, Barisella M, Gronchi A, Casali PG, Sanfilippo R.
Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.
Clin Sarcoma Res. 2017 Aug 22;7:16.
73. Spreafico F, Biondi D, Lo Vullo S, Gandola L, D'Angelo P, Terenziani M, Bianchi M, Provenzi M, Indolfi P, Pession A, Nantron M, Di Cataldo A, **Morosi C**, Perotti D, Catania S, Bellani FF, Collini P; AIEOP Wilms Tumor Working Group.

Results of the Third AIEOP Cooperative Protocol on Wilms Tumor (TW2003) and Related Considerations.
J Urol. 2017 Nov;198(5):1138-1145.

74. Greco G, Cascella T, Facciorusso A, Nani R, Lanocita R, **Morosi C**, Vaiani M, Calareso G, Greco FG, Ragnanese A, Bongini MA, Marchianò AV, Mazzaferro V, Spreafico C.
Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma.
World J Radiol. 2017 May 28;9(5):245-252.
75. Luksch R, Grignani G, D'Angelo P, Prete A, Puma N, Podda M, Casanova M, Ferrari A, **Morosi C**, Fagioli F, Aglietta M, Ferrari S, Picci P, Massimino M.
Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.
Pediatr Blood Cancer. 2017 Dec;64(12).
76. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, **Morosi C**, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Lancet Oncol. 2017 Jun;18(6):812-822.
77. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, **Morosi C**, Collini P, Stacchiotti S, Casali PG, Gronchi A.
Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.
Cancer J. 2017 Mar/Apr;23(2):86-91.
78. Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, **Morosi C**, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Eur J Cancer. 2017 May;76:84-92.
79. Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, **Morosi C**, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.
Ann Oncol. 2017 Jun 1;28(6):1230-1242.
80. Messiou C, Moskovic E, Vanel D, **Morosi C**, Benchimol R, Strauss D, Miah A, Douis H, van Houdt W, Bonvalot S. Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. Eur J Surg Oncol. 2017 Jul;43(7):1191-1198.
81. Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, **Morosi C**, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.

Eur J Cancer. 2016 Dec;69:158-165.

82. Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, **Morosi C**, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. *Ann Oncol*. 2016 Oct 11.
83. Podda MG, Luksch R, Puma N, Gandola L, Morosi C, Terenziani M, Ferrari A, Casanova M, Spreafico F, Meazza C, Catania S, Schiavello E, Biassoni V, Chiaravalli S, Massimino M. Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents. *Tumori*. 2016 Jan-Feb;102(1):84-8.
84. Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, Le Pêchoux C, Wardelman E, Winfield JM, Boulet B, Bovée J, Haas RL; European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group; European Organization for Research and Treatment of Cancer - Imaging Group. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging *Eur J Cancer*. 2016 Mar;56:37-44. doi: 10.1016/j.ejca.2015.12.008. Epub 2016 Jan 20. PMID: 26802529 Free Article Similar articles Select item 26797935
85. Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG. Sunitinib in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database *Ann Surg Oncol*. 2016 Sep;23(9):2735-44. doi: 10.1245/s10434-016-5331-z. Epub 2016 Jun 22. PMID: 27334221 Similar articles Select item 27223048
86. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG, Gronchi A. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surg Oncol*. 2016 Sep;25(3):125-31. doi: 10.1016/j.suronc.2016.05.002. Epub 2016 May 7. PMID: 27566012 Similar articles Select item 27334221
87. Colia V, Provenzano S, Morosi C, Collini P, Renne SL, Dagrada PG, Sangalli C, Dei Tos AP, Marrari A, Casali PG, Stacchiotti S. Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review *Clin Sarcoma Res*. 2016 Sep 1;6(1):16. doi: 10.1186/s13569-016-0055-1. eCollection 2016. PMID: 27588167 Free PMC Article Similar articles Select item 27566012
88. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, **Morosi C**, Baldi GG, Stacchiotti S, Casali PG, Gronchi A. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. *Eur J Cancer*. 2015 Dec;51(18):2800-7.
89. Facciorusso A, Mariani L, Sposito C, Spreafico C, Bongini M, **Morosi C**, Cascella T, Marchianò A, Camerini T, Bhoori S, Brunero F, Barone M, Mazzaferro V. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. *Gastroenterol Hepatol*. 2015 Sep 2.
90. Hindi N, Casali PG, **Morosi C**, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, Gronchi A, Stacchiotti S. Imatinib in advanced chordoma: A retrospective case series analysis. *Eur J Cancer*. 2015 Nov;51(17):2609-14.
91. Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, **Morosi C**, Camerini T, Carrara M, Pellizzari S, Negri A, Aliberti G, Sposito C, Bhoori S, Facciorusso A, Civelli E, Lanocita R, Padovano B, Migliorisi M, De Nile MC, Seregni E, Marchianò A, Crippa F, Mazzaferro V. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. *Eur J Nucl Med Mol Imaging*. 2015 Oct;42(11):1718-38
92. Pietrantonio F, Orlandi A, Inno A, Da Prat V, Spada D, Iaculli A, Di Bartolomeo M, **Morosi C**, de Braud F. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for

93. Spreafico C, **Morosi C**, Maccauro M, Romito R, Lanocita R, Civelli EM, Sposito C, Bhoori S, Chiesa C, Frigerio LF, Lorenzoni A, Cascella T, Marchianò A, Mazzaferro V. Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. *Cardiovasc Intervent Radiol*. 2015 Apr;38(2):322-8.
94. Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, **Morosi C**, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol*. 2015 Mar;39(3):383-93
95. Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, **Morosi C**, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A, Marchianò A, Mazzaferro V. Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical-Radiological Outcomes and Safety Profile. *Cardiovasc Intervent Radiol*. 2015 Feb;38(1):129-34
96. Stacchiotti S, Sommer J; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol*. 2015 Feb;16(2):e71-83
97. Tazzari M, Palassini E, Vergani B, Villa A, Rini F, Negri T, Colombo C, Crippa F, **Morosi C**, Casali PG, Pilotti S, Stacchiotti S, Rivoltini L, Castelli C. Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. *BMC Cancer*. 2015;15(1):1044
98. Provenzano S, Hindi N, **Morosi C**, Ghilardi M, Collini P, Casali PG, Stacchiotti S. Response of conventional chondrosarcoma to gemcitabine alone: a case report. *Clin Sarcoma Res*. 2015 Mar 15;5:9.
99. **Morosi C**, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, Gronchi A, Fiore M. Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: analysis of 291 consecutive patients at a tertiaryreference sarcoma center. *Eur J Surg Oncol*. 2014 Dec;40(12):1662-70.
100. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, **Morosi C**, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. *Eur J Cancer*. 2014 Nov;50(17):3021-8.
101. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, **Morosi C**, Messina A, Dei Tos AP, Gronchi A, Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res*. 2014 Nov 22;4(1):16
102. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014 Sep;25 Suppl 3:iii21-6.
103. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014 Sep;25 Suppl 3:iii113-23.
104. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014 Sep;25 Suppl 3:iii102-12.
105. Podda MG, Terenziani M, Gandola L, Collini P, Pizzi N, Marchianò A, **Morosi C**, Luksch R, Ferrari A, Casanova M, Spreafico F, Polastri D, Meazza C, Catania S, Schiavello E, Biassoni V, Massimino M. Thyroid carcinoma after treatment for malignancies in childhood and adolescence: from diagnosis through follow-up. *Med Oncol*. 2014 Aug;31(8):121.
106. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, **Morosi C**, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG. Activity of sunitinib in extraskeletal myxoid chondrosarcoma. *Eur J Cancer*. 2014 Jun;50(9):1657-64.
107. Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, **Morosi C**, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. *Br J Cancer*. 2014 Jan 7;110(1):26-33

108. Field JK, van Klaveren R, Pedersen JH, Pastorino U, Paci E, Becker N, Infante M, Oudkerk M, de Koning HJ; European Randomized Screening Trial Group. J Surg European randomized lung cancer screening trials: Post NLST. *Field Oncol.* 2013 Oct;108(5):280-6.
109. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, **Morosi C**, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. *Clin Cancer Res* 2013; 19:5192-5201.
110. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, **Morosi C**, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, Casali PG. Phase II study on lapatinib in advanced EGFR-positive chordoma. *Ann Oncol.* 2013 Jul;24(7):1931-6
111. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, **Morosi C**, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study. *Hepatology.* 2013 May;57(5):1826-37
112. Spreafico F, Gamba B, Mariani L, Collini P, D'Angelo P, Pession A, Di Cataldo A, Indolfi P, Nantron M, Terenziani M, **Morosi C**, Radice P, Perotti D; AIEOP Wilms Tumor Working Group. Loss of heterozygosity analysis at different chromosome regions in wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the italian association of pediatric hematology and oncology. *J Urol.* 2013 Jan;189(1):260-7.
113. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, Gronchi A, Dei Tos AP, **Morosi C**, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol.* 2012; 23:3171-9
114. Stacchiotti S, Verderio P, Messina A, **Morosi C**, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. *Cancer.* 2012 Dec 1;118(23):5857-66
115. Chiesa C, Mira M, Maccauro M, Romito R, Spreafico C, Sposito C, Bhoori S, **Morosi C**, Pellizzari S, Negri A, Civelli E, Lanocita R, Camerini T, Bampo C, Carrara M, Seregni E, Marchianò A, Mazzaferro V, Bombardieri E. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. *Q J Nucl Med Mol Imaging.* 2012 Dec;56(6):503-8
116. Stacchiotti S, Palassini E, Sanfilippo G.R., Vincenzi B, Arena M.G., Bochicchio A.M., De Rosa P, Nuzzo A, Turano S., **Morosi C.**, Dei Tos A.P., Pilotti S., Casali P.G.: Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. *Ann Oncol* 2012; 23:501-508
117. Reichardt P, **Morosi C**, Wardelmann E, Gronchi A. Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management. *Expert Rev Anticancer Ther.* 2012 Aug;12(8):1053-68.
118. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, **Morosi C**, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. *Lancet Oncol.* 2012 Aug;13(8):810-6.
119. Ferrari A, De Salvo GL, Oberlin O, Casanova M, De Paoli A, Rey A, Minard V, Orbach D, Carli M, Brennan B, Vannoessel MM, **Morosi C**, Stevens MC, Bisogno G. Synovial sarcoma in children and adolescents: a critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosis. *Eur J Cancer.* 2012 Jun;48(9):1370-5.
120. Spreafico C, Nicolai N, Lanocita R, **Morosi C**, Catanzaro M, Civelli E, Torelli T, Stagni S, Piva L, Frigerio LF, Marchianò A, Salvioni R. CT-guided percutaneous cryoablation of renal masses in selected patients. *Radiol Med.* 2012 Jun;117(4):593-605.
121. Pastorino U, Rossi M, Rosato V, Marchianò A, Sverzellati N, **Morosi C**, Fabbri A, Galeone C, Negri E, Sozzi G, Pelosi G, La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev.* 2012 May;21(3):308-15.
122. Salvioni R, Nicolai N, Necchi A, Torelli T, Piva L, Stagni S, Catanzaro MA, Bionani D, Milani A, Colecchia M, Spreafico C, **Morosi C**, Marchianò A, Crippa F. [The treatment of early-stage germ cell tumors of the testis (GCTT)]. *Urologia.* 2012 Apr-Jun;79(2):81-8.
123. Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, **Morosi C**, Dei Tos AP, Pilotti S, Casali PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from

the Italian Rare Cancer Network. *Ann Oncol*. 2012 Feb;23(2):501-8

124. Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, **Morosi C**, Casali PG, Gronchi A. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol*. 2012 Feb;19(2):511-8.
125. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, **Morosi C**, Gronchi A, Pilotti S, Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. *Int J Cancer*. 2011 Oct 1;129(7):1761-72.
126. Damascelli B, Ticha V, Patelli G, Lanocita R, **Morosi C**, Civelli E, Di Tolla G, Frigerio LF, Ciceri E, Garbagnati F, Spreafico C, Amadeo P, Marchianò A. Use of a Retrievable Vena Cava Filter With Low-Intensity Anticoagulation for Prevention of Pulmonary Embolism in Patients With Cancer: An Observational Study in 106 Cases *J Vasc Interv Radiol* 2011; 22:1312-9
127. Stacchiotti S, Dagrada GP, **Morosi C**, Negri T, Romanini A, Pilotti S, Gronchi A, Casali PG. Extraskelatal myxoid chondrosarcoma: tumor response to sunitinib. *Clin Sarcoma Res*. 2012 Oct 11;2(1):22.
128. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, **Morosi C**, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. *Ann Oncol*. 2011; Jul;22 (7):1682-90
129. Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A, Sposito C, **Morosi C**, Civelli E, Lanocita R, Camerini T, Bampo C, Bhoori S, Seregini E, Marchianò A, Mazzaferro V, Bombardieri E. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with 90Y microspheres: the experience of the National Tumor Institute of Milan. *Q J Nucl Med Mol Imaging*. 2011 Apr;55(2):168-97.
130. Stacchiotti S, Grosso F, Negri T, Palassini E, **Morosi C**, Pilotti S, Gronchi A, Casali PG. Tumor response to sunitinib malate observed in clear-cell sarcoma. *Ann Oncol*. 2010 May;21(5):1130-1
131. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, **Morosi C**, Messina A, Pastorino U, Pierotti MA 5, Casali PG, and Pilotti S Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response. *Mol Cancer Ther* 2010; 9:1286-1297.
132. Ferrari A, Miceli R, Meazza C, Casanova M, Favini F, **Morosi C**, Trecate G, Marchianò A, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Podda M, Catania S, Schiavello E, Giannatempo P, Gandola L, Massimino M, Mariani L. Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. *J Clin Oncol* 2010; Mar 10; 28:1322-1328
133. Ferrari A, Miceli R, Casanova M, Meazza C, Favini F, Luksch R, Catania S, Fiore M, **Morosi C**, Mariani L. The symptom interval in children and adolescents with soft tissue sarcomas. *Cancer*. 2010 Jan 1;116(1):177-83.
134. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, **Morosi C**, Gronchi A, Pilotti S, Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol*. 2009 Nov;20(11):1886-94.
135. **Morosi C**, Civelli E, Battiston C, Schiavo M, Mazzaferro V, Severini A, Marchianò A. CT cholangiography: assessment of feasibility and diagnostic reliability. *Eur J Radiol*. 2009 Oct;72(1):114-7.
136. Massimino M, Gandola L, Seregini E, Bongarzone I, **Morosi C**, Collini P. Thyroidiatrogenic sequelae after the treatment of pediatric cancer. *Q J Nucl Med Mol Imaging*. 2009 Oct;53(5):526-35.
137. Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, **Morosi C**, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. *Ann Oncol*. 2009 Aug;20(8):1439-44.
138. Casanova M, Meazza C, Favini F, Fiore M, **Morosi C**, Ferrari A. Rhabdomyosarcoma of the extremities: a focus on tumors arising in the hand and foot. *Pediatr Hematol Oncol*. 2009 Jul-Aug;26(5):321-31.
139. Marchianò A, Calabrò E, Civelli E, Di Tolla G, Frigerio LF, **Morosi C**, Tafaro F, Ferri E, Sverzellati N, Camerini T, Mariani L, Lo Vullo S, Pastorino U. Pulmonary nodules: volume repeatability at multidetector CT lung cancer screening. *Radiology*. 2009 Jun;251(3):919-25.
140. Stacchiotti S, Collini P, Messina A, **Morosi C**, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, Casali PG.

High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. *Radiology*. 2009 May;251(2):447-56.

141. Stacchiotti S, Collini P, Messina A, **Morosi C**, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, Casali PG. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. *Radiology*. 2009 May;251(2):447-56
142. Stacchiotti S, Tamborini E, Marrari A, Brici S, Rota SA, Orsenigo M, Crippa F, **Morosi C**, Gronchi A, Pierotti MA, Casali PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. *Clin Cancer Res*. 2009 Feb 1;15(3):1096-1194.
143. Meazza C, Casanova M, Zaffignani E, Luksch R, Podda M, Favini F, Catania S, Biassoni V, **Morosi C**, Ferrari A. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. *Med Oncol*. 2009; 26(1):67-72
144. Audisio RA, **Morosi C**, Bozzetti F, Cozzi G, Bellomi M, Pisani P, Pestalozza A, Gennari L, Severini A. The outcome of cholangitis after percutaneous biliary drainage in neoplastic jaundice. *HPB Surg*. 1993 Aug;6(4):287-93.
145. **Morosi C**, Ballardini G, Pisani P, Bellomi M, Cozzi G, Vidale M, Spinelli P, Severini A. Diagnostic accuracy of the double-contrast enema for colonic polyps in patients with or without diverticular disease. *Gastrointest Radiol*. 1991 Fall;16(4):345-7.
146. Cozzi G, Bellomi M, Frigerio LF, **Morosi C**, Pestalozza A, De Pedri E, Di Finizio A, Severini A. [Use of Severini's coaxial catheters in gastrointestinal interventional radiology]. *Radiol Med*. 1990 Jun;79(6):607-9.
147. Cozzi G, Ostinelli C, Bellomi M, **Morosi C**, Pestalozza A, Severini A. [Percutaneous transhepatic biliary drainage. Complications and their treatment]. *Radiol Med*. 1989 Apr;77(4):399-404. Italian. PubMed PMID: 2471232.
148. Bellomi M, Cozzi G, **Morosi C**, Frigerio LF, Pestalozza MA, Severini A. [Gastrointestinal interventional radiology. Technics and preliminary results]. *Radiol Med*. 1988 Oct;76(4):297-302. Italian.

| | |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Congress participation</p> | <ul style="list-style-type: none"> ▪ Radioembolization of Hepatocellular carcinoma with portal thrombosis: experience at Cancer Institute of Milan C. Spreafico, C. Morosi, R. Romito, M. Maccauro, R. Lanocita, E. M. Civelli, C. Chiesa, A. Marchionò, R. Mazzaferro ECR 2011 ▪ CT-Guided percutaneous cryoablation of renal masses in selected patients C. Spreafico, N. Nicolai, R. Lanocita, C. Morosi, A. Necchi, E. M. Civelli, S. Stagni, A. Marchionò, R. Mazzaferro ECR 2010 ▪ Retroperitoneal tumors: analysis of computed tomography findings and histopathologic correlation for soft tissue sarcomas C Morosi, M Fiore, E Pennacchioli, A Marchionò, S Stacchiotti, P Collini, A Messina, M Barisani, P. G. Casali, A Gronchi CTOS 2010 ▪ Unusual metastatic sites in gastrointestinal stromal tumour (GIST) R. Bertulli, E. Fumagalli, P. Coco, A. Messina, C. Morosi, P. Dileo, P. Casali; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy ASCO 2009 ▪ Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM) F. Grosso, R. Sanfilippo, R. L. Jones, P. Collini, C. Morosi, F. Raspagliesi, J. C. Tercero, M. D'Incalci, P. Judson, P. G. Casali; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Royal Marsden Hospital, London, United Kingdom; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; PharmaMar, Madrid, Spain; Mario Negri Institute for Pharmacological Research, Milan, Italy ASCO 2009 ▪ Antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT) P. G. Casali, S. Stacchiotti, E. Palassini, A. Marrari, T. Negri, C. Morosi, A. Messina, U. Pastorino, A. Gronchi, S. Pilotti; Istituto Nazionale Tumori, Milano, Italy ASCO 2009 ▪ Response to sirolimus in combination to tyrosine kinase inhibitors (TKI) in three cases of metastatic D842V metastatic gastrointestinal stromatumor(GIST) C. Piovesan, E. Fumagalli, P. Coco, E. Palassini, P. Dileo, C. Morosi, A. Gronchi, P. Casali; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy ASCO 2009 ▪ Management of complicated tumour response (CTR) to tyrosine kinase inhibitors in gastrointestinal stromal tumour (GIST) patients (pts) with locally advanced/metastatic disease P. Coco, E. Fumagalli, C. Morosi, A. Messina, R. Bertulli, S. Stacchiotti, A. Gronchi, P. Casali; Fondazione IRCCS Istituto Nazionale Tumori Milano, Milano, Italy ASCO 2009 ▪ Rechallenge with Trabectedin in patients with responding myxoid liposarcoma R. Sanfilippo, F. Grosso, E. Viridis, C. Morosi, J. C. Tercero, A. Gronchi, S. Pilotti, M. D'Incalci, P. Judson; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; PharmaMar, Madrid, Spain; Istituto Mario Negri, Milan, Italy |
| | |

I authorize the processing of my personal data contained in the CV pursuant to art. 13 of Legislative Decree 30 June 2003, n. 196 "Code regarding the protection of personal data" and of the GDPR (EU Regulation 2016/679 ")

In attachment the certificate GCP training.

Milan 10 January 2024.....

...

Morosi Carlo.....SIGNATURE